Compare Emerson Electric Co. (EMR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Emerson Electric Co. trades at $160.84 (market cap $91.20B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Emerson Electric Co. is far larger — about 12.1× Spyre Therapeutics Inc. Common Stock's market cap, and Emerson Electric Co. pays a 1.36% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EMR | SYRE | |
|---|---|---|
Market Cap | $91.20B | $7.52B |
Volume | 2,131,741 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $164.38 | $108.92 |
52-Week Low | $123.30 | $22.18 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $102.28B | $6.52B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $161.08, down 0.85% on the day, with a bullish technical signal from moving averages. The company shows solid fundamentals with a 13.83% net income margin and consistent earnings beats in recent quarters. Revenue is projected to grow to $18.6B in 2026, and analysts maintain a consensus buy rating with a $165.90 price target, suggesting modest upside. A dividend of $0.56 per share is scheduled for payment in September 2026.
EMR presents a favorable outlook supported by earnings momentum and analyst optimism, though valuation multiples like a P/E of 35.78 are elevated. Key risks include competitive pressures and macroeconomic sensitivity. The stock's proximity to resistance at $164 may prompt near-term consolidation, but fundamental strength supports long-term growth potential.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
